Multiple Myeloma Trial Results
- Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
(Posted: 01/09/2015) - Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
- Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple Myeloma
(Posted: 09/19/2013) - Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.
- Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
(Posted: 12/18/2009, Updated: 05/09/2012) - Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo.
- Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
- Less-intensive Treatment Regimen Effective against Multiple Myeloma
(Posted: 09/23/2010) - Treating patients who have multiple myeloma with less-intensive dosing of bortezomib (Velcade®) reduced toxic side effects without making the treatment less effective, Spanish researchers reported online August 23, 2010, in The Lancet Oncology.